Sh t1 of 4

FORM PTO-1449 (REV. 7-80)				DEPARTMENT OF COMMERCE INT AND TRADEMARK OFFICE	0045/0/410		SERIAL NO. 10/021780		
		INFORMATI	APPLICANT						
STATEM	IENT	BY APPLICANT	Anantanarayan et al.						
Use several sheets if necessary)						FILING DATE GRO		111111111111111111111111111111111111111	
Ope sever	<b>αι</b> 3()	eots il liocessary)	}			, ,			
		:	12/07/01		16	626			
			U.S.	PATENT DOCUMENTS			•		
EXAMINER NITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLAS	S FILIN	FILING DATE I	
40	1	3,254,093	05/1966	Huisgen et al.	260	295			
	2	3,984,431	10/1976	Gueremy et al.	260	310			
	3	4,000,281	12/1976	Beiler et al.	424	263			
	4	5,051,518	09/1991	Murray et al.	548	373			
	5	5,134,142	07/1992	Matsuo et al.	514	<b>25</b> 5			
	6	5,559,137	09/1996	Adams et al.	514	341	_		
	7	5,486,534	01/1996	Lee et al.	514	406	+		
	8	5,589,439	12/1996	Goto et al.	504	261			
	9	5,658,903	08/1997	Adams et al.	514	235.8			
	10	5,739,143	04/1998	Adams et al.	514	275		······································	
	11	5,756,529	05/1998	Isakson et al.	514	406	+		
	12	5,972,972	10/1999	Mihelich et al.	514	341			
	13	5,898,425	12/1999	Adams et al.	514	275			
	<u> </u>		FOREIGN	PATENT DOCUMENTS	1				
XAMINER IITIAL	DOCUMENT NO.		DATE	COUNTRY	CLASS SUBCL		LASS TRANSLATION		
							YES	NO	
<u> 40</u>	14	WO 83/00330	02/1983	PCT -					
	15	WO 92/19616	11/1992	РСТ					
	16	WO 95/06036	03/1995	PCT					
	17	WO 95/22545 A1	08/1995	PCT				I	
_\	18	WO 96/03385 A1	02/1996	PCT					
		<del>-</del> 1 ( )					4-		

Sh et 2 of 4

ORM PT( REV. 7-80				DEPARTMENT OF COMMERCE FENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. 3015/6/US	SERIAL NO. 10/021780		
INFORMATION DISCLOSURE					APPLICANT Anantanarayan et al,			
Use several sheets If necessary)					12/07/01	GROUP 1626		
10	19	WO 96/21452 A1	07/1996	PCT				
1	20	WQ 96/21654 A1	07/1996	РСТ		_		
	21	WO 96/40143 A1	12/1996	PCT	1			
1	22	WO 97/01551	01/1997	РСТ		_		
1	23	WO 97/23479 A1	07/1997	PCT	/			
	24	WO 97/25046 A1	07/1997	РСТ				
	25	WO 97/25047 A1	07/1997	PCT	/ /			
	26	WO 97/25048 A1	07/1997	PCT				
	27	WO 97/32583 A1	. 09/1997	PCT				
	28	WO 97/35855 A1	10/1997	PCT				
	29	WO 97/35856 A1	10/1997	PCT	. /			
	30	WO 97/47618 A1	12/1997	PCT				
	31	WO 98/07425 A1	02/1998	PCT				
	32	WO 98/16230 A1	04/1998	PCT				
	33	WO 98/25619 A1	06/1998	PCT				
	34	WO 98/52937 A2 & A3	11/1998	PCT				
	35	WO 98/52940 A1	11/1998	PCT				
	36	WO 98/52941 A1	11/1998	PCT				
	37	WO 98/57968 A1	12/1998	PCT				
	38	WO 99/01130 A1	01/1999	РСТ				
	39	WO 99/01131 A1	01/1999	PCT				
V	40	WO 99/01136 A1	01/1999	PCT				

EXAMINER 1-A. Splale	DATE CONSIDERED 6-4-03							
"EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

ATTY. DOCKET NO.

FORM PTO-1449

EXAMINER

P.38 Sheet 3 of 4

SERIAL NO.

		PATENT AND TRADEMARK OFFICE				3015/6/US 10/021780				
INFORMATION DISCLOSURE						APPLICANT				
STATEMENT BY APPLICANT (Use several sheets if necessary)						Anantanarayan et al.				
						GROUP 1626				
								41	WO 99/01452 A1	01/1999
42	WO 99/17776 A1	04/1999	PCT	-		)	-			
43	WO 99/32121 A1	07/1999	PCT							
44	WO 99/61426 A1	12/1999	PCT	0.						
45	0 115 640 A2	12/1983	EPO							
46	0 418 845 A1	03/1991	EPO ·							
47	0 515 041 A2	11/1992	EPO				·			
48	0 531 901 A2	03/1993	EPO							
49	4-145081	05/1992	JAPAN	T			X			
50	5-17470	01/1993	JAPAN				х			
51	5-345772	12/1993	JAPAN .				×			
52	8-183787	07/1996	JAPAN				х			
53	WO 94/19350	09/1994	PCT							
54	WO 95/31451	11/1995	PCT .							
<b>5</b> 5	0 846 686 A1	06/1998	EPO	7			*			
56	0 846 687 A1	06/1998	EPO							
57	DD 295 374 A5	10/1991	GERMANY							
	1 sh 4 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 66	1 sheets if necessary)  41	A1 WO 99/01452 A1 01/1999 A2 WO 99/17776 A1 04/1999 A3 WO 99/32121 A1 07/1999 A4 WO 99/61426 A1 12/1999 A5 0 115 640 A2 12/1983 A6 0 418 845 A1 03/1991 A7 0 515 041 A2 11/1992 A8 0 531 901 A2 03/1993 A9 4-145081 05/1992 A9 4-145081 05/1993 A9 4-145081 05/1998 A9 4-145081 06/1998 A9 4-145081 06/1998	Sheets if necessary    Sheets if necessary	Sheets if necessary	Sheets if necessary)   FILING DATE	Sheets if necessary			

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE

06/03/03 TUE 20:27 [TX/RX NO 8181] 2038

DATE CONSIDERED

## Sheet 4 of 4

Y	2	61	Zheng-Nian Huang, "Synthesis and Biological Activities of 1-(substituted pyrazol-4-yl)-1,2,4-triazoles", Chemical Abstracts, Volume 124, No. 23, Abstract No. 317062d, 1996.
		62	Chemical Abstracts, 13th Collective Chemical Substance Index 1992-1998, Book 51, pp. 546-550.
		63	Zhengming, Li et al., "Syntheses of Di-heterocyclic Compounds; Pyrazolylimidazoles And Isoxazolylimadazoles", Heteroatom. Chem., Vol. 9, No. 3, pp. 317-320, 1998
		64	Zheng-Nian Huang, "The Reaction Of α-ΟΧΟ-α-Triazolyketene Dithloacetal With Amines, Hydrazine And Cuanidine", Chinese Chemical Letters, Vol. 5, No. 1, pp. 31-34, 1994.
		65	Popova, A.N. et al., "Synthesis Of 4-(Pyrazol-4-yl)-Substituted Salts Of Pyryllum And Pyridines", Chemical Abstracts Vol. 098, No. 1, January 3, 1983 Abstract No. 004498.
		66	Bauer, V.J. et al., "4-3(5)-Pyrazolyl Pyridinium Salts. A New Class Of Hypoglycemic Agents", J. Med. Chem., Vol. 11; pp. 981-4, (September 1968)
		67	Cativiela, C. et al., "On the Synthesis Of 3(5)-(Carbomethoxy)-4-hetarylpyrazoles", J. Heterocycl. Chem., Vol. 25; pp 851-5, (May-June 1988)
		68	Fischer, U. et al., "1,3-Dipolar Additions To 7-Methylthieno [2,3-c]pyridine 1,1-dioxide", Helv. Chim. Acta ; Vol. 63(6), No. 180, pp. 1719-27, (1980)
		69	September 24, 1998 PCT International Search Report (PCT/US98/10436)
		70	Badger, Alison M. et al., "Disease-Modifying Activity Of SB 242235, A Selective Inhibitor Of p38 Mitogen-Activated Protein Kinase, In Rat Adjuvant-Induced Arthritis", Arthritis & Rheumatism, Vol. 43, No. 1, pp. 175-183, 2000.
		71	Henry, James R., "p38 Mitogen-Activated Protein Kinase As A Target For Drug Discovery", <i>Drugs of the Future</i> , Vol. 24, pp. 1345-1354, 1999.
		72	Satituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention Cytokine-Mediated Diseases", Current Medicinal Chemistry, Issue 6, pp. 807-823, 1999.
		73	Liverton, N.J. et al., "Design And Synthesis Of Potent, Selective, And Orally Bioavailable Tetrasubstituted Imidezole Inhibitors Of p38 Kinase Mitogen-Activated Protein Kinase", <i>J. Med. Chem.</i> , Vol. 42, pp. 2180-2190, 1999.
		74	Adams, J.L., et al., "Pyrimidinylimidazole Inhibitors Of CSBP/p38 Kinase Demonstrating Decreased Inhibition Of Hepatic Cytochrome p450 Enzymes", Bioorganic & Medicinal Chemistry Letters, Vol. 8, pp. 3111-3116, 1998.
		75	Gallagher, T.F., "Regulation Of Stress-Induced Cytokine Production By Pyridinylimidazoles; Inhibition Of CSBP Kinase", Bioorganic & Medicinal Chemistry, Vol. 5, pp. 49-64, 1997.
	·	76	Hanson, G.J., "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis", Exp. Opin. Ther. Patents, Vol. 7, pp. 729-733, 1997.
	/	77	Moerck R.E. et al., "Pyrazole Addition To Δ ¹-Azirines. Structure of Purported 2:1 Adducts of Δ ¹-Azirines With sym- Tetrazines", J.Chem. Soc., Chem. Commun., No. 19, pp. 782-783 (1974).

EXAMINER	1.	H-	Solola		DATE CONSIDERED	6-4-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.